A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Prostate cancer is a leading cause of cancer death in men, with limited treatment options for advanced stages.
• Prostate-specific membrane antigen (PSMA) is a highly expressed target on prostate cancer cells, making it a viable target for therapy.
• Novel immunotherapies are urgently needed to address treatment resistance in advanced prostate cancer.

Purpose of the Study:

• To develop and evaluate a novel recombinant immunotoxin targeting prostate-specific membrane antigen (PSMA) for prostate cancer therapy.
• To assess the specificity and efficacy of the A5-PE40 immunotoxin against PSMA-positive prostate cancer cells.
• To determine the therapeutic potential of A5-PE40 in preclinical models of prostate cancer.

Main Methods:

• Construction of a recombinant immunotoxin (A5-PE40) using a single-chain variable fragment (scFv) against PSMA and a truncated Pseudomonas exotoxin A (PE40).
• Generation of the scFv A5 antibody fragment via phage display technology and selection on PSMA-expressing cells.
• Bacterial expression and purification of the A5-PE40 immunotoxin for in vitro testing.

Main Results:

• The A5-PE40 immunotoxin demonstrated specific binding to PSMA-positive prostate cancer cells.
• A5-PE40 induced a 50% reduction in cancer cell viability (IC50) at a concentration of 20 pM.
• PSMA-negative cells remained unaffected, indicating high specificity of the immunotoxin.

Conclusions:

• The recombinant immunotoxin A5-PE40 exhibits potent and specific toxicity against PSMA-expressing prostate cancer cells.
• A5-PE40 represents a promising therapeutic candidate for advanced prostate cancer treatment.
• Further investigation of A5-PE40 is warranted for clinical applications in prostate cancer patients.